Pharma Focus Europe

NextPoint Therapeutics' NPX887 Clears FDA IND for Reactivating Immune Cells in HHLA2+ Solid Tumors

Friday, December 08, 2023

NextPoint Therapeutics, a biotechnology company in the clinical stage, has disclosed the acceptance of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) for NPX887. The company has outlined plans to initiate a Phase I clinical trial in early 2024 to assess NPX887 in patients with solid tumors expressing HHLA2, a tumor antigen that is significantly upregulated in various human cancers.

Dr. Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics, emphasized, “NPX887 marks our second clinical program concentrating on the HHLA2 checkpoint axis. Our strategy at NextPoint involves advancing therapeutics targeting this axis from diverse perspectives to impede tumors from avoiding immune system detection. This crucial development enables us to progress with the clinical evaluation of NPX887, bringing us one step closer to our goal of expanding treatment options for cancer patients.”

NPX887 is a fully human monoclonal antibody designed to target HHLA2 (B7-H7), an immune checkpoint and tumor target antigen prevalent in many cancers, independent of PD-L1. The therapeutic objective of NPX887 is to inhibit immune evasion in solid tumors by blocking KIR3DL3-mediated immunosuppression upon binding to HHLA2. The treatment is anticipated to enhance T and NK cell anti-tumor activity within the tumor microenvironment.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva